Share on StockTwits

bluebird bio (NASDAQ:BLUE) CEO Nick Leschly unloaded 42,925 shares of the stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $40.02, for a total value of $1,717,858.50. Following the transaction, the chief executive officer now directly owns 372,659 shares of the company’s stock, valued at approximately $14,913,813. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

BLUE has been the subject of a number of recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of bluebird bio in a research note on Wednesday. They now have a $53.00 price target on the stock, up previously from $44.00. Separately, analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday. Finally, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $42.48.

Shares of bluebird bio (NASDAQ:BLUE) traded up 0.52% on Wednesday, hitting $36.66. The stock had a trading volume of 379,511 shares. bluebird bio has a 52 week low of $17.03 and a 52 week high of $41.75. The stock’s 50-day moving average is $23.17 and its 200-day moving average is $22.64. The company’s market cap is $898.6 million.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.32) by $0.12. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.23 million. Analysts expect that bluebird bio will post $-1.78 EPS for the current fiscal year.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.